| Dermatitis, Atopic
Eucrisa vs Zoryve Cream
Side-by-side clinical, coverage, and cost comparison for dermatitis, atopic.Deep comparison between: Eucrisa vs Zoryve with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsZoryve has a higher rate of injection site reactions vs Eucrisa based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Zoryve but not Eucrisa, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Eucrisa
Zoryve
At A Glance
Topical
Twice daily
PDE-4 inhibitor
Topical
Daily
PDE4 inhibitor
Indications
- Dermatitis, Atopic
- Psoriasis vulgaris
- Dermatitis, Atopic
Dosing
Dermatitis, Atopic Apply a thin layer twice daily to affected areas; once clinical effect is achieved, consider reducing to once daily. For topical use only.
Psoriasis vulgaris Apply ZORYVE cream, 0.3%, to affected areas once daily in adult and pediatric patients 6 years of age and older.
Dermatitis, Atopic Apply ZORYVE cream, 0.15%, once daily for patients 6 years of age and older; apply ZORYVE cream, 0.05%, once daily for pediatric patients 2 to 5 years of age.
Contraindications
- Known hypersensitivity to crisaborole or any component of the formulation
- Moderate to severe liver impairment (Child-Pugh B or C)
Adverse Reactions
Most common (>=1%) Application site pain
Postmarketing Allergic contact dermatitis
Most common (>=1%), Plaque Psoriasis Diarrhea, headache, insomnia, nausea, application site pain, upper respiratory tract infection, urinary tract infection
Most common (>=1%), Atopic Dermatitis Headache, nausea, application site pain, diarrhea, vomiting, upper respiratory tract infection, rhinitis, conjunctivitis
Pharmacology
Crisaborole is a phosphodiesterase 4 (PDE-4) inhibitor; PDE-4 inhibition results in increased intracellular cyclic adenosine monophosphate (cAMP) levels, though the specific mechanism by which it treats atopic dermatitis is not well defined.
PDE4 inhibitor; roflumilast and its active metabolite (roflumilast N-oxide) inhibit PDE4, a major cyclic AMP-metabolizing enzyme, leading to accumulation of intracellular cyclic AMP.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Eucrisa
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (10/12) · Qty limit (9/12)
Zoryve
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (9/12) · Qty limit (9/12)
UnitedHealthcare
Eucrisa
- Covered on 4 commercial plans
- PA (1/8) · Step Therapy (4/8) · Qty limit (5/8)
Zoryve
- Covered on 4 commercial plans
- PA (6/8) · Step Therapy (4/8) · Qty limit (4/8)
Humana
Eucrisa
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (3/3)
Zoryve
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (3/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Eucrisa.
$0
Arcutis Cares Patient Assistance: ZoryveCommercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
EucrisaView full Eucrisa profile
ZoryveView full Zoryve profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.